VISIBLY, INC. – Trademark Portfolio
Entity Type: 03
VISIBLY, INC. holds 10 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 9 filings in this category. The portfolio also extends into Class 44 (Medical Services) across 3 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include LENSIO, EYECARELIVE, OPTERNATIVE, LENSESFORLESS, and VISIBLY EYE CARE FOR ALL. The owner is based in CHICAGO, IL.
#233
207 EAST OHIO STREET
CHICAGO, IL 60611
Showing of trademarks Trademarks
Trademark Classifications
VISIBLY, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Advertising; business management; business administration; office functions
Frequently Asked Questions
How many trademarks does VISIBLY, INC. have?
VISIBLY, INC. has 10 U.S. trademarks filed with the USPTO. Of these, 6 registered, 3 abandoned, 1 cancelled.
What trademark classes does VISIBLY, INC. file in?
VISIBLY, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). Class 42 covers scientific and technological services; industrial analysis and research services.
What are VISIBLY, INC.'s most well-known trademarks?
VISIBLY, INC.'s registered trademark portfolio includes well-known marks such as LENSIO, EYECARELIVE, OPTERNATIVE, LENSESFORLESS, and VISIBLY EYE CARE FOR ALL. These are among 6 currently registered trademarks in the portfolio.
What is VISIBLY, INC.'s trademark registration success rate?
VISIBLY, INC. has a 60% trademark registration rate, with 6 out of 10 resolved applications resulting in successful registration. Currently, 0 applications are pending review.